{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:02:41Z","timestamp":1790287361153,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/rhu.0b013e31823e2e35","type":"journal-article","created":{"date-parts":[[2011,12,13]],"date-time":"2011-12-13T07:47:15Z","timestamp":1323762435000},"page":"1-7","source":"Crossref","is-referenced-by-count":24,"title":["Giant Cell Arteritis in Mexican Patients"],"prefix":"10.1097","volume":"18","author":[{"given":"Marco A.","family":"Alba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Mena-Madrazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe","family":"Flores-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210207","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.berh.2010.10.008","article-title":"Epidemiology of large-vessel vasculidities.","volume":"24","author":"Richards","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R2-1-20210207","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/md.0b013e31803d1764","article-title":". Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study.","volume":"86","author":"Gonzalez-Gay","year":"2007","journal-title":"Medicine"},{"key":"R3-1-20210207","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/bjo.2006.108845","article-title":". Epidemiology of giant-cell arteritis in an Arab population: a 22-year study.","volume":"91","author":"Chaudhry","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R4-1-20210207","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/art.11195","article-title":". Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey.","volume":"49","author":"Kobayashi","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R5-1-20210207","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0161-6420(01)00574-7","article-title":". The epidemiology of giant cell arteritis: a 12-year retrospective study.","volume":"108","author":"Liu","year":"2001","journal-title":"Ophthalmology"},{"key":"R6-1-20210207","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ajo.2006.07.048","article-title":". Giant cell arteritis among Hispanic Americans.","volume":"143","author":"Lam","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R7-1-20210207","first-page":"304","article-title":". Temporal arteritis in Puerto Rico Hispanics.","volume":"98","author":"Guerra","year":"2006","journal-title":"Bol Asoc Med P R"},{"key":"R8-1-20210207","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":". The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"key":"R9-1-20210207","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/rheumatology\/ken480","article-title":". High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.","volume":"48","author":"Berger","year":"2009","journal-title":"Rheumatology"},{"key":"R10-1-20210207","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","article-title":". Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment.","volume":"41","author":"Gonzalez-Gay","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R11-1-20210207","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MD.0b013e3181af4518","article-title":". Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis.","volume":"88","author":"Gonzalez-Gay","year":"2009","journal-title":"Medicine"},{"key":"R12-1-20210207","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/01.md.0000180042.42156.d1","article-title":". Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients.","volume":"84","author":"Gonzalez-Gay","year":"2005","journal-title":"Medicine"},{"key":"R13-1-20210207","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.md.0000180043.19285.54","article-title":". Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients.","volume":"84","author":"Gonzalez-Gay","year":"2005","journal-title":"Medicine"},{"key":"R14-1-20210207","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","article-title":". Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis.","volume":"41","author":"Cid","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R15-1-20210207","first-page":"1272","article-title":". Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course.","volume":"30","author":"Liozon","year":"2003","journal-title":"J Rheumatol"},{"key":"R16-1-20210207","doi-asserted-by":"crossref","first-page":"162","DOI":"10.7326\/0003-4819-88-2-162","article-title":". Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study.","volume":"88","author":"Huston","year":"1978","journal-title":"Ann Intern Med"},{"key":"R17-1-20210207","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1002\/art.27753","article-title":". Genetically determined Amerindian ancestry correlates with increased frequency of risk alleles for systemic lupus erythematosus.","volume":"62","author":"Sanchez","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R18-1-20210207","first-page":"520","article-title":". Geographical and genetic factors do not account for significant differences in the clinical spectrum of giant cell arteritis in Southern Europe.","volume":"31","author":"Gonzalez-Gay","year":"2004","journal-title":"J Rheumatol"},{"key":"R19-1-20210207","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2796.2002.01042.x","article-title":". Fever of unknown origin in the elderly.","volume":"252","author":"Tal","year":"2002","journal-title":"J Intern Med"},{"key":"R20-1-20210207","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":". EULAR recommendations for the management of large vessel vasculitis.","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R21-1-20210207","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/rheumatology\/36.2.251","article-title":". Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis.","volume":"36","author":"Font","year":"1997","journal-title":"Br J Rheumatol"},{"key":"R22-1-20210207","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.20171","article-title":". Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.","volume":"50","author":"Nesher","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R23-1-20210207","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semarthrit.2007.10.014","article-title":". The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis.","volume":"38","author":"Lopez-Diaz","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"R24-1-20210207","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1002\/art.22141","article-title":". Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.","volume":"54","author":"Lee","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R25-1-20210207","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.md.0000119761.27564.c9","article-title":". Risk factors for cranial ischemic complications in giant cell arteritis.","volume":"83","author":"Nesher","year":"2004","journal-title":"Medicine"},{"key":"R26-1-20210207","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.md.0000145369.25558.b5","article-title":". Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis.","volume":"83","author":"Gonzalez-Gay","year":"2004","journal-title":"Medicine"},{"key":"R27-1-20210207","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","article-title":". Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis.","volume":"48","author":"Salvarani","year":"2009","journal-title":"Rheumatology"},{"key":"R28-1-20210207","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0161-6420(98)91033-8","article-title":"Scalp necrosis with giant cell arteritis.","volume":"105","author":"Dudenhoefer","year":"1998","journal-title":"Ophthalmology"},{"key":"R29-1-20210207","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.084947","article-title":". Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss.","volume":"68","author":"Chatelain","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R30-1-20210207","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0002-9343(01)00770-7","article-title":". Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients.","volume":"111","author":"Liozon","year":"2001","journal-title":"Am J Med"},{"key":"R31-1-20210207","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-122-7-199504010-00004","article-title":"Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study.","volume":"122","author":"Evans","year":"1995","journal-title":"Ann Intern Med"},{"key":"R32-1-20210207","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-83-6-806","article-title":". Large artery involvement in giant cell (temporal) arteritis.","volume":"83","author":"Klein","year":"1975","journal-title":"Ann Intern Med"},{"key":"R33-1-20210207","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F","article-title":". Disease pattern in cranial and large-vessel giant cell arteritis.","volume":"42","author":"Brack","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R34-1-20210207","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.11353","article-title":". Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, andor large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years.","volume":"48","author":"Nuenninghoff","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R35-1-20210207","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.0954-6820.1986.tb02796.x","article-title":"Long-term corticosteroid treatment in giant cell arteritis.","volume":"220","author":"Andersson","year":"1986","journal-title":"Acta Med Scand"},{"key":"R36-1-20210207","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/ard.52.12.847","article-title":"The clinical and laboratory course of polymyalgia rheumaticagiant cell arteritis after the first two months of treatment.","volume":"52","author":"Kyle","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"R37-1-20210207","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":". Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R38-1-20210207","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/art.20541","article-title":". Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis.","volume":"51","author":"Garcia-Martinez","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R39-1-20210207","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MD.0b013e31821c4fad","article-title":". Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from Northwestern Spain.","volume":"90","author":"Martinez-Lado","year":"2011","journal-title":"Medicine"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00124743-201201000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:31:51Z","timestamp":1786048311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00124743-201201000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e31823e2e35","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}